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young adult males. Genotype I is prevalent. With
time some of the patients become HDV RNA negative
or asymptomatic carrier. Most of the patients have
suppressed HBV DNA replication. Significant numbers of
patients have cirrhosis.
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Abstract
AIM: To assess the clinical presentation and genotypes
of delta hepatitis in local population.
METHODS: In this prospective study, 39 consecutive
patients who were positive for HBsAg and hepatitis
D virus (HDV) antibody were included. The patients
were divided in two groups on the basis of presence
or absence of HDV RNA and a comparative study was
done. Genotype of HDV was determined in PCR positive
patients.
RESULTS: Overall there is male dominance, in which
34 patients out of 39 (87.2%) were male. Twenty
(51%) patients were from the adjacent areas of three
provinces; Sindh, Punjab and Balochistan indicating the
higher prevalence of delta hepatitis in this mid region
of Pakistan. Patients of all age groups were affected
with delta hepatitis (median 31.5 years, range 12-75).
HDV RNA was detectable in 23 patients (59%). All
the HDV strains belonged to genotype I . HBV DNA
was detectable only in 3 cases who were also HBeAg
and HDV RNA positive. Patients with detectable HDV
RNA were younger than patients with undetectable
RNA; mean age 29.7 ± 12.8 years vs 36.8 ± 15.2.
There were no statistically significant differences in the
clinical presentation and routine biochemical profile
of patients with detectable or undetectable HDV RNA.
Clinical cirrhosis was present in 19 (49%) patients; 12
with detectable RNA and 7 with undetectable HDV RNA
(P = 0.748). Decompensated disease was seen in eight
patients; five and three respectively from each group.
Four patients with undetectable RNA and two patients
with detectable RNA had normal ALT and ultrasound
abdomen.
CONCLUSION: HDV may infect at any age, usually
www.wjgnet.com
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INTRODUCTION
Up to 5% of the world's population is infected with
hepatitis B virus (HBV), and probably 5% of the HBV
carriers have hepatitis D virus (HDV) superinfection[1]. It
is estimated that 15 million people are infected with HDV
worldwide [2]. Superinfection of HDV in persons with
HBV infection leads to progressive disease and cirrhosis
in approximately 80% of cases[3]. Cirrhosis develops at a
younger age than in patients with chronic HBV infection
alone[4].
In Pakistan viral hepatitis remains a serious health
problem. Recent data suggested that 16.6% of patients
infected with hepatitis B vir us also suffered from
superimposed delta infection [5] . However, local data
is based on serology of HDV and PCR studies were
not done. It is not clear how many of local patients
spontaneously recover from the infection and how these
patients differ from patients with persistent infection.
Moreover, the genotype of the virus in Pakistan is also
unknown.
The nucleotide sequences of hepatitis D viruses (HDV)
vary 5% to 14% among isolates of the same genotype
and 23% to 34% among different genotypes[6,7]. Based on
the analysis of HDV genomes from different areas of
the world, three genotypes of HDV have been identified.
Genotype I is the most prevalent worldwide and is
associated with a broad spectrum of pathogenecity. It is
predominant in the Europe, United States and the Middle
East and has some geographically based subtypes[7,8]. In
the Far East, the predominant genotype is genotypeII.
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Patients infected with this genotype have significantly
lower ALT levels, more favorable outcomes and a trend
to have lower serum HDV RNA levels as compared with
those infected with genotype I [9]. However II b variant may
be associated with progressive disease[10]. Type III genotype
is predominant in northern South America and has been
associated with severe forms of hepatitis[11].
We evaluated our patients in terms of genotype and
prognosis and compared the HDV RNA positive patients
with the negative group.

MATERIALS AND METHODS
Thirty nine patients who were HBsAg and HDV antibody
positive for more than six months were further tested for
HDV RNA. These patients were divided into two groups;
the first group included a total of 23 patients which were
HDV RNA positive by PCR reflecting active ongoing
delta infection while the second group consisted of a total
of 16 patients with undetectable HDV RNA reflecting
previous exposure to delta hepatitis or viral load less than
the sensitivity of assay used for the HDV RNA. Markers
for hepatitis B activity were done in all of these which
included HBeAg, Anti-HBe antibody, and HBV DNA.
Extraction and RT-PCR analysis of HDV RNA
HDV RNA was isolated from patients' serum samples
by High Pure Viral RNA isolation kit according to the
manufacturer's instructions (Roche Diagnostics, USA).
RNA was eluted from spin columns provided with the
kit in sterile nuclease free water and stored at -80℃
until further analysis. Later, RNA samples were reverse
transcribed into cDNA using 1st Strand cDNA Synthesis
Kit for RT-PCR (Roche Diagnostics, USA). Briefly, cDNA
mix consisted of reaction buffer containing 5 mmol/L
MgCl2, RNA, random primers, 50 units RNAse inhibitor
and AMV reverse transcriptase. The reaction was carried
out for 90 min at 42℃ in a thermal cycler. The resulting
cDNA was amplified with sequence specific primers for
HDV according to the published method[12]. The amplified
products were separated on a 1.5% agarose gel and a 400
bp product indicated the presence of HDV in the sample.
To monitor the quality of the assay in each test run both
negative and positive controls were included.
HDV genotyping by RT-PCR and RFLP assay
Serum samples of patients which showed presence of
HDV RNA were genotyped according to the pub-lished
method of Ivaniushia et al[13] 2000. After PCR amplification
with primers specific for HDAg coding region, positive
samples were digested overnight at 37℃ with restriction
enzyme SmaI. Genotype I, II and III were confirmed and
classified according the sizes of the fragments following
SamI digestion.
Extraction and amplification of HBV DNA
HBV DNA was extracted using High Pure Viral Nucleic
Acid isolation assay as indicated by the manufacturer
(Roche Diagnostics). Sequences of primers, specific for
core region of HBV genome, used for amplification were
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previously reported[14]. Each PCR reaction consisted of
reaction buffer, 0.2 mmol/L deoxyribonucleotides, 1.5
mmol/L MgCl 2, 100 ng of each primer, and 2 U Taq
polymerase in a final volume of 50 µ L. All standard
precautions were taken during the study to prevent cross
contamination between PCR samples.
Serological tests
HBe 2.0 assay (Abbott, USA), which is based on microparticle
enzyme immunoassay technology, was employed for the
detection of HBeAg levels in sera. For running the assay,
the AxSYM system was used according to the manufacture's
instruction (Abbott, USA). Anti-HDV antibody test was
performed by Murex competitive enzyme immunoassay as
suggested by the manufacturer (Abbott, Chicago IL, USA).
Clinical aspects
The clinical features of patients with detectable HDV
RNA were compared with HDV RNA negative patients
to determine the clinical impact of continuous presence
o f H DV R N A a n d o u t c o m e f o r H DV i n fecti o n .
Informed consent was taken and a standardized pro
forma was completed regarding laboratory and serological
data, complications of liver disease to include ascites,
hematemesis and melena, portosystemic encephalopathy
(PSE), hepatocellular carcinoma (HCC), and Childs-Pugh
score. The study was approved by the Ethics Review
Committee of the Medicare Clinic.
The patients were labeled suffering from clinical
cirrhosis on the basis of clinical and ultrasound findings
suggestive of cirrhosis (nodular surface, firm consistency,
blunt liver edge, altered echotexture, dilated portal vein
and splenomegaly) and evidence of hypersplenism (platelets
< 15 000/mm3).
Statistical analysis
Results were analyzed using Special package for Social
Sciences software (SPSS version 13.0, Chicago, IL,
USA). Data was summarized as the means with standard
deviations (for continuous variables), and as frequency
and percentages (for categorical variables). Univariate
analysis was done using Mann Whitney U-test, and Fischer
exact test wherever appropriate. P < 0.05 was considered
significant. All P-values were two sided.

RESULTS
Overall there is male dominance, in which 34 out of 39
(87.2%) patients were male. These patients belonged to
the different areas of country. Of those, 12 came from
upper parts of Sindh Province, 15 were from the lower
Sindh including Karachi, 8 from Balochistan Province and
4 from the lower parts of Punjab Province. Out of these,
20 (51%) patients were from the adjoining districts of
upper Sindh, Punjab and Balochistan Provinces. Patients
of all the age groups were affected with delta hepatitis,
the disease was seen as early as the second decade of life
to as late as the mid 70's (range 12-75, median 31.5, mode
22), but the majority of patients in both the groups were
adults.
www.wjgnet.com
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Table 1 Characteristics of hepatitis delta patients

Male:Female
Age (yr)
Clinical cirrhosis
Decompensated disease
Normal ultrasound and ALT
HBe antigen
HBV DNA
Bilirubin (mg/dL)
ALT (U/L)
AST (U/L)
GGT U/L
ALP (U/L)
Albumin (g/dL)
Hemoglobin (g/dL)
Total leucocyte count (× 109/L)
Platelets (× 109/L)
INR

RNA detected
(n = 23)
20:3
29.7 ± 12.8
12 (52%)
5 (22%)
2 (9%)
3 (13%)
3 (13%)
1.8 ± 2.0
88 ± 45
81 ± 52
99 ± 121
124 ± 56
3.4 ± 0.7
12.3 ± 2.0
6.1 ± 2.0
143 ± 84
1.3 ± 0.2

RNA not detected
(n = 16)
14:4
36.8 ± 15.2
7 ((44%)
3 (19%)
4 (25%)
1 (6%)
0
2.9 ± 5.6
125 ± 199
150 ± 280
49 ± 31
100 ± 31
3.4 ± 0.9
12.9 ± 1.8
5.0 ± 1.8
157 ± 85
1.2 ± 0.1

ALT: alanine aminotransferase; AST: aspartate aminotransferase; GGT:
gamma glutamyl transpeptidase; ALP: alkaline phosphatase; INR:
international normalization ratio. Values are means ± SD, or n (%). There are
no statistically significant differences among the two groups.

The clinical presentation of ant-HDV positive patients
was jaundice in 11 (28%), ascites 3 (7.7%), encephalopathy
3 (7.7%), and hematemesis 2 (5.1%). Nine patients
gave the history of hospitalization due to liver related
indication. On examination the liver was palpable in 4
(10.3%) and splenomegaly in 17 (43.6%). Laboratory
investigations included hemoglobin 12.5 ± 1.9 g/dL,
total leucocyte count 5.7 ± 2.0 × 109/L, platelets 151 ±
66 × 109/L, INR 1.25 ± 0.16, bilirubin 2.2 ± 3.7 mg/dL,
alanine aminotransferase (ALT) 103 ± 131 IU/L, aspartate
aminotransferase (AST) 109 ± 179 IU/L, gamma glutamyl
traspeptitase (GGT) 81 ± 101 IU/L, alkaline phosphatase
116 ± 49 IU/L.
HDV RNA was detectable in 23 patients (59%). All of
these patients belonged to genotype I of the virus. Viral
markers of hepatitis B replication, serum HBeAg and
HBV DNA, were absent in a majority of the cases in both
the groups. HBV DNA was detectable only in 3 cases.
These patients had HBeAg positive disease and were also
positive for HDV RNA. None of the HDV RNA negative
patients were positive for HBV DNA though one such
patient was positive for HBeAg.
Patients with detectable HDV RNA were younger than
patients with undetectable RNA; age 29.7 ± 12.8 years
vs 36.8 ± 15.2, though the difference was not statistically
significant (95% CI-2.68-16.8). There was no statistically
significant difference in the clinical presentation and
routine biochemical profile of patients with detectable or
undetectable HDV RNA (Table 1). Clinical cirrhosis was
present in 19 (49%) patients; 12 (52%) with detectable
RNA and 7 (43%) with undetectable HDV RNA (P =
0.748). Out of these, decompensated disease (history of
hematemesis, ascites, and encephalopathy) was seen in 8
patients; 5 patients with detectable RNA and 3 without
detectable HDV RNA. Four patients with undetectable
RNA and 2 patients with detectable RNA had normal
www.wjgnet.com
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ALT and ultrasound abdomen. These 6 patients were HBV
DNA and HBeAg negative.

DISCUSSION
Clinical studies of HDV disease worldwide indicate
that there is a wide variation in the clinical presentation.
The manifestations of HDV infection vary from benign
acute hepatitis to fulminant hepatitis and from rapidly
progressive chronic liver disease to an asymptomatic carrier
state [15]. The clinical course was influenced by several
factors, including the HDV genotype[9]. In our study all of
the patients were infected with genotype I . This is new
data from this region. Our previous study indicates, that in
Pakistan, there is a predominant genotype of Hepatitis B
is genotype D[16]. The association of genotype I of HDV
with genotype D of HBV has been reported from other
countries where HBV genotype D is predominant as is in
Italy[17], Turkey[18] and Egypt[19]. This genotype may cause a
wide spectrum of pathogenecity. In the South East Asia,
the predominant HDV genotype is II and HBV genotype
B and C. Genotype II is associated with a less rapidly
progressive course of chronic liver disease[9].
Local data regarding the hepatitis D strain is based
upon presence of anti-HDV antibody due to nonavailability of PCR facility. The percentage of patients who
spontaneously recover from hepatitis D is not known. A
recent study involving the clinical presentation of hepatitis
delta from Pakistan based on anti-HDV antibody, showed
that HDV infection was present in 16.6% of hepatitis B
infected patients in Pakistan, most commonly in younger
males living in rural areas. Delta antibody positive patients
had less severe clinical liver disease compared to delta
negative, hepatitis B patients[5]. HDV RNA status of the
patients was not known in that series. In our study again
majority of HDV antibody positive patients, 34 patients
out of 39 (87.2%), were male. Most of these patients were
young adults and came from from upper part of Sindh,
lower Punjab and adjacent areas of Balochistan Province.
These adjoining areas of three provinces for m the
hepatitis belt in Pakistan, the area with higher prevalence
of hepatitis. In our study, clinical cirrhosis was present in
about half of the patients so the present data adds further
information on severity of liver disease associated with
HDV genotype 1 in Pakistan.
It may not be difficult to predict whether HDV was
acquired as a coinfection with HBV or as a superinfection
in patients with existing chronic HBV infection. Natural
history of HDV infection shows that coinfection evolves
to chronicity only in a small number of patients and
patients recover from both hepatitis B and D, while
superinfection of HDV leads to progressive disease and
cirrhosis in approximately 80% of cases[3]. Our patients
were in the chronic phase. It can be assumed that most of
our HDV RNA positive patients acquired the infection as
a superinfection on hepatitis B.
In most cases of HDV infection, HBV replication is
suppressed to very low levels by HDV[20,21]. In our series,
all the cases were negative for HBV DNA except three
who were positive for HBV DNA, HBe antigen and HDV
RNA. It seems that HBV replication is not suppressed
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by the presence of HDV RNA in a subset of subjects. A
more ominous course toward liver decompensation has
been documented in patients with active HBV and HDV
replication [15] with each virus contributing to the liver
damage, thereby resulting in more severe liver disease[22].
All the three of our patients who were both HBV DNA
and HDV RNA positive, had clinical cirrhosis.
Our patients with detectable HDV RNA were younger
than patients with undetectable RNA. Absence of HDV
RNA in our 16 (41%) patients signifies that a proportion
of patients lose the virus with increasing age or viral titres
become too low to be detectable by the assay we use.
Four patients with undetectable RNA and two patients
with detectable RNA had normal ALT and ultrasound
abdomen. These patients were HBV DNA negative. The
former four represent spontaneous recovery while later
two were probably the asymptomatic carriers. This state
has been reported previously[15,23].
In summary, HDV genotype I is prevalent in our
patients. HDV may infect at any age, usually young adult
males. With time, some of the patients become a HDV
RNA negative or an asymptomatic carrier. Most of the
patients have suppressed HBV DNA replication. A significant number of patients have cirrhosis.
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